ATF6 Modulator Compounds for Unfolded Protein Response Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing therapies fail to effectively modulate the ATF6 arm of the Unfolded Protein Response (UPR) to address various diseases and conditions, including cancer, neurodegeneration, and ischemia/reperfusion injury, due to its complex integration with multiple stress-responsive pathways.
Innovation Solution
Development of compounds that modulate ATF6 signaling, either activating or inhibiting its activity, to provide therapeutic benefits in diseases mediated by ATF6, such as cancer, neurodegenerative diseases, and vascular diseases, by administering specific compounds that target ATF6.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional small molecules or biologic macromolecules are used as immunosuppressants, then immunosuppression effect is achieved, but side effects increase and/or immunogenicity occurs
Solution Approach 1:
The patent changes the molecular structure parameters by introducing a novel bicyclic core structure with specific substituent patterns (R1-R6 groups) to achieve optimal balance between immunosuppression efficacy and reduced side effects. The general formula (I) structure with its specific bicyclic framework represents a parameter optimization that distinguishes it from conventional small molecules and biologics
Solution Approach 2:
The patent creates a composite molecular structure combining elements of small molecule drugs with the specific bicyclic core framework. This composite approach integrates the stability of small molecules with the targeted immunosuppression mechanism, achieving a balance between efficacy and reduced immunogenicity that neither conventional small molecules nor biologic macromolecules can achieve alone
2Reliability
If existing immunosuppressants are used to prevent organ rejection, then rejection prevention is achieved, but infection and malignancy risks increase
Solution Approach 1:
The patent applies local quality by designing the bicyclic core structure with specific functional groups positioned at defined locations (R1-R6 substituents) to achieve localized interaction with immune cell targets. This localized molecular design allows for selective immunosuppression at the cellular level while minimizing systemic side effects, thereby reducing infection and malignancy risks
3Reliability
If conventional immunosuppressants are administered, then immunosuppression is achieved, but compliance decreases due to complex dosing regimens
Solution Approach 1:
The patent optimizes pharmacokinetic parameters through the novel bicyclic structure design, achieving improved bioavailability, extended half-life, and consistent plasma concentration profiles. These parameter changes enable simplified dosing regimens with fewer administrations per day, directly improving patient compliance while maintaining reliable immunosuppression
Data Source
AI summary
Compounds (I) as modulators of Activating Transcription Factor 6 (ATF6) are provided. The compounds may find use as therapeutic agents for the treatment of diseases or disorders mediated by ATF6 and may find particular use in the treatment of viral infections, neurodegenerative diseases, vascular diseases, or cancer.